BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Rhea-AI Summary
Bio Green Med Solution (NASDAQ: BGMS) reported Q4 and full-year 2025 results, highlighting the Sept 12, 2025 acquisition of Fitters, sale of plogosertib for $300,000 plus a potential $170,000 milestone, and liquidation of its U.K. subsidiary.
As of Dec 31, 2025 cash totaled $3.5M, product revenue from fire-safety sales was $0.7M, net loss for 2025 was $3.0M, and the company estimates cash runway into Q3 2026.
Positive
- Acquisition of Fitters completed on September 12, 2025
- Sale of plogosertib for $300,000 plus potential $170,000 milestone
- Product revenue $0.7M from fire-safety sales in 2025
- Operating cash outflow reduced to $4.8M from $8.0M
Negative
- Cash balance declined to $3.5M as of December 31, 2025
- Net loss of $3.0M for the year ended December 31, 2025
- General and administrative expenses rose to $7.7M in 2025
News Market Reaction – BGMS
On the day this news was published, BGMS gained 3.84%, reflecting a moderate positive market reaction. This price movement added approximately $156K to the company's valuation, bringing the market cap to $4.21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Biotechnology / Pharmaceutical Preparations group were flagged in the momentum scanner; current setup appears stock-specific rather than sector-driven.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Quarterly earnings | Neutral | -2.2% | Q3 2025 results and business update on transition to fire safety. |
Limited earnings history in the new business model; the prior earnings update saw a modest -2.24% move after results.
In its prior earnings on Nov 13, 2025, BGMS highlighted Q3 2025 results showing $3.8M cash, early fire safety revenues of $81k, and zero R&D expense after the U.K. subsidiary liquidation. That update also detailed the transition from biopharma to fire safety distribution and multiple capital structure changes, including reverse splits and warrant exchanges. Today’s full-year 2025 report extends that story with completed asset sales, expanded fire safety revenue and a reduced annual net loss.
Historical Comparison
Over the past year, BGMS has only one comparable earnings release, which saw a -2.24% move, offering limited but slightly negative precedent for reactions to financial updates.
Earnings disclosures trace a shift from oncology R&D toward fire safety distribution, with asset sales, subsidiary liquidation and warrant exchanges reshaping the balance sheet.
Market Pulse Summary
This announcement details BGMS’s full-year 2025 transition, with net loss narrowing to $3.0M, operating cash use reduced to $4.8M, and cash of $3.5M expected to fund operations into the third quarter of 2026. The shift away from R&D, sale of plogosertib for $300,000 plus milestones, and $0.7M in fire safety revenue highlight a new direction. Investors may watch future revenue growth, cost control, and additional financing steps closely.
Key Terms
Asset Purchase Agreement financial
Warrant Exchange Agreement financial
Convertible Exchangeable Preferred Stock financial
polo-like kinase 1 (PLK 1) inhibitor medical
hematological malignancies medical
bioavailability medical
AI-generated analysis. Not financial advice.
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.
“2025 was a productive year for BGMS, marked by the acquisition of Fitters Sdn. Bhd., a fire safety materials and equipment company, on September 12, 2025, the liquidation of our U.K. subsidiary and the sale of our Plogosertib drug, transactions which strengthened our balance sheet. We used this momentum to chart our new focus towards continued growth in the company,” said Datuk Dr. Doris Wong Sing EE, Chief Executive Officer of BGMS.
Fourth Quarter 2025 Key Accomplishments and Recent Highlights
- In October, the Company entered into an Asset Purchase Agreement with Tethra Biosciences Inc., a Delaware corporation, in which the Company agreed to sell certain assets, including all of the Company’s patent rights related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies for a purchase price of
$300,000 , plus a further potential Milestone payment of$170,000 . - In November, the Company entered into a Warrant Exchange Agreement with holders of certain existing warrants of the Company, which were exchanged for 1,402,605 shares of the Company’s common stock, par value
$0.001 per share, which warrants were originally issued pursuant to a securities purchase agreement dated as of June 20, 2025. - In January 2026, the Board of Directors of the Company declared a quarterly cash dividend of
$0.15 per share on the Company’s6% Convertible Exchangeable Preferred Stock, which was paid on February 1, 2026, to holders of record as of the close of business on January 22, 2026.
Financial Highlights
As of December 31, 2025, cash and cash equivalents totaled
Net cash used in operating activities was
Following the acquisition of Fitters Sdn. Bhd. on September 12, 2025, product revenue from sales and distribution of fire safety equipment was
Cost of sales related to sales and distribution of fire safety equipment were
Research and development (R&D) expenses were
General and administrative expenses for the three months and year ended December 31, 2025, were
Total other income, net, for the three months and year ended December 31, 2025, was
Income tax charges for the three months and year ended December 31, 2025 were
Net loss for the three months and year ended December 31, 2025, was
About Bio Green Med Solution, Inc.
BGMS is a diversified company that was formerly engaged in the biopharmaceutical industry but as of September 2025 has shifted its operations to focus on provision of fire safety protection and distribution activities. Specifically, on September 12, 2025, the Company completed its acquisition of Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services. Headquartered in Malaysia, the Company is now focused on advancing opportunities across these distinct sectors whilst maintaining its commitment to driving long-term value creation for shareholders. For additional information, please visit www.bgmsglobal.com.
Forward-looking Statements
Except for historical information, certain matters discussed in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve various assumptions, known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or other comparable words. Actual results, performance or outcomes may differ materially from those expressed or implied by these forward-looking statements and may not align with historical performance and events due to a number of factors, including those discussed in the sections of our annual report on Form 10-K entitled “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors,” and those discussed in our Form 10-Q quarterly reports filed after such annual report. BGMS’s SEC filings are readily obtainable at no charge at www.sec.gov, as well as on its own investor relations website at https://investor.bgmsglobal.com/sec-filings. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements, and caution should be exercised against placing undue reliance upon such statements, which are based only on information currently available to us and speak only as of the date hereof. We are under no duty to update publicly any of the forward-looking statements after the date of this earnings press release, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE:
Bio Green Med Solution, Inc.
info@bgmsglobal.com
BIO GREEN MED SOLUTION, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)
(In
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue - fire safety | $ | 666 | $ | - | $ | 747 | $ | - | ||||||||
| Clinical trial supply | - | - | - | 43 | ||||||||||||
| Revenues | $ | 666 | $ | - | 747 | 43 | ||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales | 545 | - | 609 | - | ||||||||||||
| Research and development | (47 | ) | 880 | 848 | 6,655 | |||||||||||
| General and administrative | 1,250 | 946 | 7,717 | 5,392 | ||||||||||||
| Total operating expenses | 1,748 | 1,826 | 9,174 | 12,047 | ||||||||||||
| Operating loss | (1,082 | ) | (1,826 | ) | (8,427 | ) | (12,004 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Foreign exchange gains (losses) | 98 | (60 | ) | 73 | (54 | ) | ||||||||||
| Interest income | 45 | 30 | 62 | 12 | ||||||||||||
| Gain on deconsolidation of subsidiary | - | - | 4,947 | - | ||||||||||||
| Other income, net | 333 | - | 354 | 52 | ||||||||||||
| Total other income, net | 476 | (30 | ) | 5,436 | 10 | |||||||||||
| Loss before taxes | (606 | ) | (1,856 | ) | (2,991 | ) | (11,994 | ) | ||||||||
| Income tax benefit (charge) | (5 | ) | (1,194 | ) | (7 | ) | 782 | |||||||||
| Net loss | (611 | ) | (3,050 | ) | (2,998 | ) | (11,212 | ) | ||||||||
| Dividend on convertible exchangeable preferred shares | (20 | ) | - | (61 | ) | - | ||||||||||
| Deemed dividend on warrant exchange | (9,539 | ) | - | (11,033 | ) | - | ||||||||||
| Net loss applicable to common shareholders | $ | (10,170 | ) | $ | (3,050 | ) | $ | (14,092 | ) | $ | (11,212 | ) | ||||
| Basic and diluted earnings per common share: | ||||||||||||||||
| Net loss per share – basic and diluted (common shareholders) | $ | (2.21 | ) | $ | (847.61 | ) | $ | (6.45 | ) | $ | (502.46 | ) | ||||
| Weighted average common shares outstanding | 4,606,822 | 3,597 | 2,185,075 | 22,314 | ||||||||||||
BIO GREEN MED SOLUTION, INC.
CONSOLIDATED BALANCE SHEET
(In
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,505 | $ | 3,137 | ||||
| Accounts receivable | 1,257 | - | ||||||
| Inventory | 1,384 | - | ||||||
| Prepaid expenses and other current assets | 110 | 537 | ||||||
| Total current assets | 6,256 | 3,674 | ||||||
| Property and equipment, net | 137 | 3 | ||||||
| Right-of-use lease asset | 12 | 5 | ||||||
| Goodwill | 1,570 | - | ||||||
| Non-current deposits | 210 | 412 | ||||||
| Total assets | $ | 8,185 | $ | 4,094 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 617 | $ | 4,599 | ||||
| Accrued and other current liabilities | 715 | 1,669 | ||||||
| Other liabilities measured at fair value | - | - | ||||||
| Total current liabilities | 1,332 | 6,268 | ||||||
| Lease liability | 2 | - | ||||||
| Other liabilities | 9 | - | ||||||
| Total liabilities | 1,343 | 6,268 | ||||||
| Stockholders’ equity | 6,842 | (2,174 | ) | |||||
| Total liabilities and stockholders’ equity | $ | 8,185 | $ | 4,094 | ||||
